Person:
SEÇKİN GENÇOSMANOĞLU, DİLEK

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

SEÇKİN GENÇOSMANOĞLU

First Name

DİLEK

Name

Filters

20172
Reset filters

Settings

Author: SALMAN, ANDAÇ × Subject: ETANERCEPT ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Tumor necrosis factor-alpha inhibitors for the treatment of psoriasis patients with liver cirrhosis: A report of four cases with a literature review
    (MEDKNOW PUBLICATIONS & MEDIA PVT LTD, 2017) SALMAN, ANDAÇ; Ergun, Tulin; Seckin-Gencosmanoglu, Dilek; Salman, Andac; Qzgen, Zuleyha; Ocak, Esra Sarac; Avsar, Erol; Imeryuz, Nese
    Patients with psoriasis are at an increased risk of developing liver disease due to various factors. The existing data regarding the treatment of psoriasis patients with associated liver cirrhosis is limited. We report four patients of psoriasis with liver cirrhosis who were treated with TNF-alpha inhibitors for a mean duration of 35.4 months. Two patients were treated with etanercept, one with adalimumab and one was treated with both infliximab and etanercept. Three patients tolerated the treatment well without any deterioration of liver disease whereas one died of progressive liver disease. Although large-scale, controlled studies are needed, this case series provides insights regarding the long-term safety of TNF-alpha inhibitors in patients with psoriasis and liver cirrhosis.
  • No Thumbnail Available
    PublicationMetadata only
    Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: A multicenter, cohort study
    (WILEY, 2017) SALMAN, ANDAÇ; Ergun, Tulin; Seckin Gencosmanoglu, Dilek; Alpsoy, Erkan; Bulbul-Baskan, Emel; Saricam, Merve Hatun; Salman, Andac; Onsun, Nahide; Sarioz, Abdullah
    The data on long-term efficacy, safety and drug survival rates of conventional systemic therapeutics in pediatric psoriasis is lacking. The primary aim of this study is to investigate acitretin, methotrexate, cyclosporin efficacy, safety and drug survival rates in pediatric patients as well as predictors of drug survival. This is a multicenter study including 289 pediatric cases being treated with acitretin, methotrexate and cyclosporin in four academic referral centers. Efficacy, adverse events, reasons for discontinuation, 1, 2- and 3-year drug survival rates, and determinants of drug survival were analyzed. A 75% reduction of Psoriasis Area and Severity Index score or better response rate was obtained in 47.5%, 34.1% and 40% of the patients who were treated with acitretin, methotrexate and cyclosporin, respectively. One-year drug survival rates for acitretin, methotrexate and cyclosporin were 36.3%, 21.1% and 15.1%, respectively. The most significant determinant of drug survival, which diminished over time, was treatment response whereas arthritis, body mass index and sex had no influence. Although all three medications are effective and relatively safe in children, drug survival rates are low due to safety concerns at this age group. Effective disease control through their rational use can be expected to improve survival rates.